Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators

Molecular Pharmacology

Volumn 76, Issue 4, 2009, Pages 778-790

  Surrel, Fanny ^a   Jemel, Ikram ^a   Boilard, Eric ^a   Bollinger, James G ^b   Payré, Christine ^a   Mounier, Carine M ^a   Talvinen, Kati A ^c   Laine, Veli J O ^c   Nevalainen, Timo J ^c   Gelb, Michael H ^b   Lambeau, Gérard ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; ICOSANOID; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2 GROUP X; PHOSPHOLIPASE A2 RECEPTOR; PROSTAGLANDIN E2; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL PROLIFERATION; COLON; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; GENE MUTATION; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASE SEQUENCE; BIOCATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION; LIPIDS; MICE; PHOSPHOLIPASES A2; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 70349328098     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053371     Document Type: Article

References (40)

1. Baker DL, Desiderio DM, Miller DD, Tolley B, and Tigyi GJ (2001) Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 292:287-295. (Pubitemid 32458097)
2. 2 in colon tumor cells potentiates tumor growth. Mol Carcinog 46:106-116.
3. 2 as targets for anti-cancer drugs. Biochem Pharmacol 74:949-959.
4. Cupillard L, Koumanov K, Mattéi MG, Lazdunski M, and Lambeau G (1997) Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem 272:15745-15752. (Pubitemid 27265549)
5. 2 in mouse tissues at protein and mRNA levels. Biochim Biophys Acta 1761:745-756.
6. Ferry G, Moulharat N, Pradère JP, Desos P, Try A, Genton A, Giganti A, Beucher- Gaudin M, Lonchampt M, Bertrand M, et al. (2008) S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 327:809-819.
7. 2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci 13:4144-4174.
8. Forest V, Pierre F, Bassonga E, Meflah K, Olivier C, and Menanteau J (2003) Apc+/Min colonic epithelial cells express TNF receptors and ICAM-1 when they are co-cultured with large intestine intra-epithelial lymphocytes. Cell Immunol 223:70-76. (Pubitemid 36945551)
9. 2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80:919-927.
10. Fujita Y, Yoshizumi M, Izawa Y, Ali N, Ohnishi H, Kanematsu Y, Ishizawa K, Tsuchiya K, and Tamaki T (2006) Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 147:1377-1385. (Pubitemid 43244372)
11. 2 in intestine in Crohn's disease. Am J Gastroenterol 94:713-720.
12. 2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med 204:865-877.
13. 2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem 280:28044-28052.
14. 2 deletion enhances colon tumorigenesis. Cancer Res 65:2636-2643.
15. 2 in a human pancreatic cancer cell line. FEBS Lett 407:343-346.
16. Kita Y, Ohto T, Uozumi N, and Shimizu T (2006) Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta 1761:1317-1322. (Pubitemid 44738706)
17. Kita Y, Takahashi T, Uozumi N, and Shimizu T (2005) A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed- phase liquid chromatography-tandem mass spectrometry. Anal Biochem 342:134-143. (Pubitemid 40805637)
18. 2. Annu Rev Biochem 77:495-520.
19. min-induced intestinal neoplasia. Cell 81:957-966.
20. Masuda S, Murakami M, Takanezawa Y, Aoki J, Arai H, Ishikawa Y, Ishii T, Arioka M, and Kudo I (2005) Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J Biol Chem 280:23203-23214. (Pubitemid 40853232)
21. 2s act on distinct cellular phospholipid molecular species. Biochim Biophys Acta 1771:1389-1396.
22. 2 formation during colon tumorigenesis. FEBS Lett 487:262-266.
23. 2-III as a biomarker candidate. Br J Cancer 98:587-595.
24. Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, and Kudo I (2005) Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2. J Biol Chem 280:24987-24998. (Pubitemid 40934591)
25. 2. Review. Biochim Biophys Acta 1781:1-9.
26. 2) genes in human colorectal adenocarcinomas. Cancer Lett 182:175-182.
27. Parrill AL and Baker DL (2008) Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 8:917-923.
28. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD, and Capdevila JH (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279:29797-29804. (Pubitemid 38915863)
29. 2 to the mouse M-type receptor. Biochemistry 46:1647-1662.
30. 2: the Nterminal region is more important than enzymatic activity. Biochemistry 45:5800-5816.
31. 2 superfamily and its group numbering system. Biochim Biophys Acta 1761:1246-1259.
32. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, Sadilek M, Nguyen E, Lazdunski M, Lambeau G, et al. (2002). Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 277:48535-48549. (Pubitemid 35470814)
33. 2: elucidation of sites for enhanced binding. J Med Chem 49:2858-2860.
34. 2 for phosphatidic acid. Biochem J 321:737-741.
35. 2 in prostate cancer. Cancer Res 64:6934-6940.
36. Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, and Taketo MM (2000). Suppression of intestinal polyposis in ApcΔ716 knockout mice by an additional mutation in the cytosolic phospholipase A2 gene. J Biol Chem 275:34013-34016. (Pubitemid 30819157)
37. 2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome. Acta Pharmacol Sin 24:1292-1296.
38. Triggiani M, Granata F, Frattini A, and Marone G (2006) Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 1761: 1289-1300, 2006. (Pubitemid 44738703)
39. Wang D and Dubois RN (2006) Prostaglandins and cancer. Gut 55:115-122.
40. Whitehead RH, VanEeden PE, Noble MD, Ataliotis P, and Jat PS (1993) Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci U S A 90:587-591. (Pubitemid 23028908)